$AVPT

AvePoint chief legal officer sells $141,100 in stock

AvePoint's CLO, Brian Michael Brown, sold 10,000 shares for $141,100 on September 30, 2026, under a 10b5-1 plan. AVPT stock has risen 54% in six months. Analysts from BMO, D.A. Davidson, Cantor Fitzgerald, and Stephens have issued positive ratings and price targets, citing strong growth prospects in AI-driven data management.

Original reporting
Published Oct 13, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 2:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AVPT
Bearish
medium confidence
Mentioned
$AVPT
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AVPTBearishLow
01

Why it matters

Primary disclosure of a Form 4 insider sale; modest novelty with limited price impact.

02

Market read

The filing provides a fresh, albeit small, data point for traders monitoring insider activity; broader market relevance is limited.

03

What to watch

Analyst upgrades and price‑target raises mentioned in the article may offset any negative sentiment from the insider sale.

Relevance 4/10Novelty 4/10Timing: immediate upon filing release

Background

The article reports an insider sale and summarizes recent analyst coverage that is not new information.

Company-level read

Ticker impact

$AVPTBearishMedium confidence
Context

Chief Legal Officer Brian M. Brown sold 10,000 AVPT shares for $141,100 under a Rule 10b5‑1 plan, disclosed in a Form 4 filing.

Expected impact

likely slight downward pressure as investors price the insider divestiture

Evidence & confidence

C‑level insider sales, even modest, are often interpreted as a lack of confidence; the amount is small relative to float, so impact is limited.

Market effects

Minimal effect on the broader data‑management software sector; AVPT remains a small cap within the industry.

U.S. market only; no notable regional ripple.

Low; the filing does not influence global market dynamics.

Counterpoint

The sale could be purely liquidity‑driven under the pre‑established 10b5‑1 plan, not a bearish signal.

Key entities

  • Brian M. Brown

    Chief Legal Officer and Director of AvePoint, Inc.

  • AvePoint, Inc.

    Provider of data‑management solutions, ticker AVPT.

Related articles

$AVPTMedAI 9/10

AvePoint (AVPT) Q2 2026 Earnings Call Transcript

AvePoint (AVPT) reported Q2 2026 revenue of $124.5M, up 22% YoY, with SaaS revenue $98.5M (79% of total). Total ARR was $465.1M (+27%), net new ARR $29.9M, and GAAP operating margin 8.2%. Full-year guidance: ARR $522.1M-$528.1M and revenue $508.5M-$512.5M. The company also spent $50M on share repurchases in Q2.

$AVPTHighAI 9/10

AvePoint lifts annual recurring revenue guidance after Q2

AvePoint reported Q2 2026 revenue of $124.5M and raised full-year annual recurring revenue guidance. SaaS revenue was $98.5M, up 27% y/y, and ARR ended at $465.1M, up 27%. Q3 revenue is forecast at $128.2M to $130.2M, and full-year ARR at $522.1M to $528.1M. The company cited demand for AI governance.

$AVPTHigh

AvePoint Announces Second Quarter 2026 Financial Results

AvePoint, Inc. (AVPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 AvePoint Announces Second Quarter 2026 Financial Results Second quarter SaaS revenue of $98.5 million, representing 27% year-over-year growth, 26% on a constant currency basis Second quarter Total revenue of $124.5 million, representing 22% year-over-year growth, 21%

$BEAMMedAI 8/10

Beam Therapeutics reports early data on gene therapy for GSDIa

Beam Therapeutics (BEAM) reported early Phase 1/2 trial data for BEAM-301, a gene therapy for GSDIa, showing dose-dependent improvements in fasting hypoglycemia and reduced starch intake. The trial enrolled six patients, with median follow-up of 313 days for the 20 mg cohort and 53 days for the 40 mg cohort. All patients experienced adverse events, but no serious safety concerns were reported. The company will discuss the data at an investor event on October 27.

$MRKLow

Merck appoints Paul Diaz to board of directors

Merck & Co. (NYSE:MRK) announced Paul J. Diaz, managing partner at Cressey & Company, will join its board of directors effective November 1, 2026. Diaz will stand for election by shareholders in May 2027, expanding the board to 14 members. He brings healthcare industry leadership experience from roles at Myriad Genetics and Kindred Healthcare.